Abstract
BackgroundCheckpoint inhibitors acting against PD-1 and CTLA-4 have provided significant benefit for patients. However, their efficacy in rare tumors has not been determined. This abstract presents the results of combination...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
